• 1
    Plunkett W, Huang P, Xu Y, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995; 22: 310.
  • 2
    Moore M, Andersen J, Burris H, et al. A randomized trial of gemcitabine (GEM) versus 5FU as first-line therapy in advanced pancreatic cancer [abstract]. Proc ASCO. 1995; 14: A473.
  • 3
    Braakjuis BJ, Ruiz van Harpere VW, Boven E, et al. Schedule-dependent antitumor effect of gemcitabine in in vivo model systems. Semin Oncol. 1995; 22: 4246.
  • 4
    Merimsky O, Meller I, Flusser G, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a Phase II study. Cancer Chemother Pharmacol. 2000; 45: 177181.
  • 5
    Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993; 11: 12691275.
  • 6
    Brennan MR, Casper ES, Harrison LB. Sarcomas of the soft tissues and bone. In: DeVitaVT, HellmanS, RosenbergSA, editors. Cancer principles and practice of oncology. 5th ed. J.B. Lippincott Company, 1997: 7381788.
  • 7
    Edmonson JH. Needed: qualitative improvement in antisarcoma therapy. J Clin Oncol. 1995; 13: 15311533.
  • 8
    Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457481.
  • 9
    SAS/STAT User's Guide, Version 7. Cary, NC: SAS Institute, Inc., 1989.
  • 10
    Le Cesne A, Judson I, Crowther D, et al. Randomized Phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma group. J Clin Oncol. 2000; 18: 26762684.
  • 11
    Antman K, Crowley J, Balcerzak SP, et al. An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993; 11: 12761285.
  • 12
    Blanke CD, von Mehren M, Joensuu H, et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571 in patients (Pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117) [abstract]. Proc ASCO. 2001; 20: 1a(1).
  • 13
    van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet. 2001; 358: 14211423.
  • 14
    Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors in advanced soft tissue sarcoma (STS): an overview of 1742 patients treated with doxorubicin containing first line regimens by the EORTC Soft Tissue and Bone Sarcoma group (STBSG). Ann Oncol. 1994; 2( Suppl 8): 171.
  • 15
    Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001; 19: 34833489.
  • 16
    Brambilla L, Labianca R, Ferrucci SM, et al. Treatment of classical Kaposi's sarcoma with gemcitabine. Dermatology. 2001; 202: 199122.
  • 17
    Hensley ML, Venkatraman E, Maki R, et al. Docetaxel plus gemcitabien is active in leiomyosarcomas: results of a Phase II trial [abstract]. Proc ASCO. 2001; 20: 1408a.
  • 18
    Spath-Schwalbe E, Genvresse I, Kaschuth A, et al. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs. 2000; 11: 325329.